Arteriovenous Fistula Market: Industry Analysis, Key Companies, Emerging Drugs and Treatment by DelveInsight | Vascular therapies, Bard Peripheral Vascular, Intact Vascular and Many Others

Arteriovenous Fistula Market: Industry Analysis, Key Companies, Emerging Drugs and Treatment by DelveInsight | Vascular therapies, Bard Peripheral Vascular, Intact Vascular and Many Others

“Arteriovenous Fistula Market”

Arteriovenous Fistula is an abnormal connection between an artery and a vein. Normally, blood flows from the arteries to the capillaries and into the veins. Nutrients and oxygen in the blood travel from capillaries to tissues in the body. With an arteriovenous fistula, blood flows directly from an artery into a vein, bypassing some capillaries, which leads to diminished blood supply in the tissues below the bypassed capillaries. Causes of arteriovenous fistulas include cardiac catheterization, injuries that pierce the skin, being born with an arteriovenous fistula, genetic conditions (such as Osler-Weber-Rendu disease, also known as hereditary hemorrhagic telangiectasia), and/or surgical creation (AV fistula procedure).

DelveInsight’s “Arteriovenous Fistula Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Arteriovenous Fistula, historical and forecasted epidemiology as well as the Arteriovenous Fistula market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Arteriovenous Fistula Market Key Facts

  • Another study by Pisoni et al. titled “Vascular access use in Europe and the United States: Results from the DOPPS” found that AVF was used by 80% of EUR countries (France, Germany, Italy, Spain, and the United Kingdom) and 24% of US prevalent patients. 
  • According to a study conducted by Woodside et al. titled “Arteriovenous Fistula Maturation in Prevalent Hemodialysis Patients in the United States: A National Study”, wherein 45,087 new AVFs were placed in 39,820 prevalent hemodialysis patients. In addition, only 54.7% of AVFs were used within 4 months of placement, with maturation rates varying considerably across end-stage renal disease (ESRD) networks.
  • As per the United States Renal Data System, in 2016, 80% of patients were using a catheter at hemodialysis (HD) initiation. Out of these, arteriovenous (AV) fistula use at HD initiation rose from 12-17% over the period 2005-2016. The percentage of patients using an AV fistula or with a maturing AV fistula at HD initiation increased from 28.9-33.4% over the same period.


Get a Free Sample Copy of the Report at:


The dynamics of the Arteriovenous fistula market is anticipated to change in the coming years owing to the positive outcomes of the emerging therapies by major key players. The launch of emerging therapies is expected during the forecast period.

Arteriovenous Fistula Companies:

  • Vascular therapies
  • Bard Peripheral Vascular 
  • Intact Vascular
  • Alucent Biomedical
  • And many others. 


Arteriovenous Fistula Therapies:

  • Sirogen
  • Angioplasty with balloon impregnated with paclitaxel
  • Tack Endovascular System
  • And many more.

Get a Free Sample Copy of the Report at:


Key Benefits of Arteriovenous Fistula Market Report:

  • Arteriovenous Fistula market report provides an in-depth analysis of Arteriovenous Fistula Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
  • The Arteriovenous Fistula market report will help in developing business strategies by understanding the Arteriovenous Fistula Market trends & developments, key players, and future market competition that will shape and drive the Arteriovenous Fistula market in the upcoming years.
  • The Arteriovenous Fistula market report covers Arteriovenous Fistula market growth and current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
  • The report provides a detailed assessment of the Arteriovenous Fistula patient population, market drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors. 


Get a Free Sample Copy of the Report at:


Table of Content

  1. Key Insights
  2. Executive Summary 
  3. Arteriovenous Fistula Competitive Intelligence Analysis
  4. Arteriovenous Fistula Market Overview at a Glance
  5. Arteriovenous Fistula Disease Background and Overview
  6. Arteriovenous Fistula Patient Journey
  7. Arteriovenous Fistula Epidemiology and Patient Population
  8. Arteriovenous Fistula Treatment Algorithm, Current Treatment, and Medical Practices
  9. Arteriovenous Fistula Unmet Needs
  10. Key Endpoints of Arteriovenous Fistula Treatment
  11. Arteriovenous Fistula Marketed Products
  12. Arteriovenous Fistula Emerging Therapies
  13. Arteriovenous Fistula Seven Major Market Analysis
  14. Attribute Analysis
  15. Arteriovenous Fistula Market Outlook (7 major markets)
  16. Arteriovenous Fistula Access and Reimbursement Overview
  17. KOL Views on the Arteriovenous Fistula Market.
  18. Arteriovenous Fistula Market Drivers
  19. Arteriovenous Fistula Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States